• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[波兰慢性阻塞性肺疾病中度和重度加重的门诊和住院费用比较]

[Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].

作者信息

Jahnz-Rózyk Karina, Targowski Tomasz, From Sławomir

机构信息

Zakład Immunologii i Alergologii Klinicznej Wojskowego Instytutu Medycznego w Warszawie Kierownik.

出版信息

Pneumonol Alergol Pol. 2008;76(6):426-31.

PMID:19173191
Abstract

INTRODUCTION

The aim of the study was to examine the direct and indirect costs of COPD exacerbations under usual clinical practice in primary and secondary care from a societal perspective in Poland.

MATERIAL AND METHODS

An observational, prospective study was conducted among patients with exacerbation of moderate or severe COPD. Seventy-three patients were included in the study - 39 treated in hospital (HC) and 34 treated in ambulatory care (AC). The direct costs included the cost of drugs, diagnostic tests, in-hospital and outpatient care. The indirect costs included costs of transportation to the health-care provider and work days lost.

RESULTS

The mean duration of COPD exacerbation did not differ significantly between the groups [HC: 11.2 (CI 95%: 9.6-12.8) days; AC: 10.8 (CI 95%: 9.1-12.1); p > 0.05]. The total health-care cost per exacerbation was EUR 1197 (4137.9 PLN) in secondary care (the HC group), and it was 6 times higher than the total cost of exacerbation in primary care (the AC group) - EUR 199.8 (446.9 PLN). The costs of drugs and diagnostic tests were significantly higher in the HC group than in the AC group; however, it was the cost of in-hospital stay and medical visits in the HC group that most influenced expenditure related to COPD exacerbations, as they were 27 times higher than in the AC group.

CONCLUSIONS

In Poland the costs of COPD exacerbation managed in secondary care are 6-fold higher than in primary care. Therefore, the decisions about admission of patients with COPD exacerbation to hospital should be made carefully.

摘要

引言

本研究旨在从波兰社会角度,考察在初级和二级医疗常规临床实践中慢性阻塞性肺疾病(COPD)急性加重的直接和间接成本。

材料与方法

对中重度COPD急性加重患者进行了一项观察性前瞻性研究。73例患者纳入研究,其中39例在医院治疗(HC组),34例在门诊治疗(AC组)。直接成本包括药物、诊断检查、住院和门诊护理费用。间接成本包括前往医疗服务提供者的交通费用和误工天数。

结果

两组间COPD急性加重的平均持续时间无显著差异[HC组:11.2(95%CI:9.6 - 12.8)天;AC组:10.8(95%CI:9.1 - 12.1);p > 0.05]。二级医疗(HC组)中每次急性加重的总医疗成本为1197欧元(4137.9波兰兹罗提),比初级医疗(AC组)中急性加重的总成本高6倍 - 199.8欧元(446.9波兰兹罗提)。HC组的药物和诊断检查成本显著高于AC组;然而,HC组的住院费用和医疗就诊费用对COPD急性加重相关支出影响最大,因为它们比AC组高27倍。

结论

在波兰,二级医疗中管理COPD急性加重的成本比初级医疗高6倍。因此,对于COPD急性加重患者是否入院的决策应谨慎做出。

相似文献

1
[Comparison of outpatient and inpatient costs of moderate and severe exacerbations of chronic obstructive pulmonary disease in Poland].[波兰慢性阻塞性肺疾病中度和重度加重的门诊和住院费用比较]
Pneumonol Alergol Pol. 2008;76(6):426-31.
2
[Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study].[2007年波兰多中心研究中慢性阻塞性肺疾病加重期在初级和二级医疗保健中的费用]
Pol Merkur Lekarski. 2009 Mar;26(153):208-14.
3
[Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland].[波兰门诊治疗的慢性阻塞性肺疾病患者的费用]
Pneumonol Alergol Pol. 2011;79(5):337-42.
4
Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan.台湾某三级医疗环境中慢性阻塞性肺疾病的成本分析。
Respirology. 2008 Sep;13(5):689-94. doi: 10.1111/j.1440-1843.2008.01308.x. Epub 2008 May 29.
5
[Retrospective analysis of direct costs of hospital treatment of chronic obstructive pulmonary disease exacerbations].[慢性阻塞性肺疾病急性加重期住院治疗直接费用的回顾性分析]
Pol Merkur Lekarski. 2004 May;16 Suppl 1:91-4.
6
[Relationship between disease severity, smoking index age and direct costs of hospital treatment of COPD exacerbations].[慢性阻塞性肺疾病急性加重期疾病严重程度、吸烟指数年龄与住院治疗直接费用之间的关系]
Pneumonol Alergol Pol. 2005;73(1):32-5.
7
[Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].[阿奇霉素治疗住院患者和门诊慢性阻塞性肺疾病急性加重的临床疗效及直接成本评估]
Pol Merkur Lekarski. 2004 May;16 Suppl 1:96-9.
8
The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.中度和重度慢性阻塞性肺疾病加重对加拿大医疗保健系统造成的成本。
Respir Med. 2008 Mar;102(3):413-21. doi: 10.1016/j.rmed.2007.10.010. Epub 2007 Dec 20.
9
Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.长期护理机构中医疗保险受益人的慢性阻塞性肺疾病负担
Am J Geriatr Pharmacother. 2009 Oct;7(5):262-70. doi: 10.1016/j.amjopharm.2009.11.003.
10
[Active tobacco smoking as determinant of costs of inpatient treatment of COPD exacerbations].[主动吸烟作为慢性阻塞性肺疾病急性加重期住院治疗费用的决定因素]
Przegl Lek. 2004;61(10):1049-51.